Renal risk
Scientists have found that a drug commonly used to prevent excessive bleeding during cardiac surgery may double the chances of kidney failure.
The patients injected with aprotinin, marketed as Trasylol by German pharma giant Bayer, were twice as likely to develop kidney problems and suffer from heart disorders as controls who received other drugs, scientists from the California-based non-profit organisation Ischemia Research and Education Foundation said. Trasylol inhibits enzymes involved in the clot-dissolving process, thereby hastening clotting. The researchers examined the effect of Trasylol in 4,374 cardiac surgery patients, who were given either the drug or a placebo.
The scientists also found the risk of heart attack or heart failure was 55 per cent greater amongst Trasylol users. Following the study that appeared in the New England Journal of Medicine (Vol 354, No 4, January 26, 2006), the US Food and Drug Administration issued a public health advisory calling for minimising the use of the drug.
Significantly, another study published in the online version of Transfusion on January 20 reported that Trasylol administration may increase the risk of renal toxicity.
Related Content
- Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study
- Particulate matter air pollution and the risk of incident CKD and progression to ESRD
- Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015
- Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants
- Long-term exposure to ambient fine particulate matter and renal function in older men: The VA Normative Aging Study
- Extent of arsenic contamination and its impact on the food chain and human health in the Eastern Ganges Basin: a review